Exploring the mechanism of modified <italic>Gexia Zhuyu Decoction</italic> (膈下逐瘀汤) in chronic salpingitis-induced infertility with qi stagnation and blood stasis syndrome based on the TLR4/MyD88/NF-κB/NLRP3 signa

<sec> <title>目的</title> 观察膈下逐瘀汤加减方基于TLR4/MyD88/NF-κB/NLRP3信号通路对气滞血瘀型输卵管炎性不孕(SOI)大鼠输卵管组织结构的影响。 </sec> <sec> <title>方法</title> 制备慢性SOI病证结合模型,使用膈下逐瘀汤加减方和TLR4通路抑制剂TAK-242进行干预后,采集各组大鼠血浆、血清及输卵管组织,采用酶联免疫吸附测定法(ELISA)检测大鼠血清中白介素1β(IL-1β)、肿瘤坏死因子α(TNF-α)水平;血液流变学检测气滞血瘀状态;HE染色观察输卵管组织病理变化;免疫组化法检测TLR4、NLRP3表达水平;RT-pcr、WB检测TLR4、MyD88、NF-κB、NLRP3、Bax、Bcl-2 mRNA及蛋白表达水平;观察各组大鼠受孕率。 </sec> <sec> <title>结果</title> 与模型组大鼠相比,中药组血浆粘度、全血粘度3.0显著降低;中药组及抑制剂组血清IL-1β、TNF-α含量显著降低,组织中TLR4、MyD88、NF-κB、NLRP3、Bax mRNA及蛋白表达降低,Bcl-2 mRNA及蛋白表达升高,输卵管病理状态改善,大鼠受孕率增加。 </sec> <sec> <title>结论</title> 膈下逐瘀汤加减方能通过TLR4/MyD88/NF-κB/NLRP3通路治疗气滞血瘀型慢性SOI,减少凋亡,TAK-242可以发挥类中药作用改善疾病的炎性指标、病理状态,但是对中医证候无明显效果。 </sec>

Authors

Publication Details

Journal
Lishizhen medicine and materia medica research
Published
2025-04-01
DOI
https://doi.org/10.70976/j.1008-0805.szgygy-2025-0706
Primary Topic
Immune Response and Inflammation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Exploring the mechanism of modified &lt;italic&gt;Gexia Zhuyu Decoction&lt;/italic&gt; (膈下逐瘀汤) in chronic salpingitis-induced infertility with qi stagnation and blood stasis syndrome based on the TLR4/MyD88/NF-&kappa;B/NLRP3 signa

Wenmin Yuan, Shangxin Dong, Nan Li, Li Liu et al.
Lishizhen medicine and materia medica research
Immune Response and Inflammation
article

Exploring the mechanism of modified &lt;italic&gt;Gexia Zhuyu Decoction&lt;/italic&gt; (膈下逐瘀汤) in chronic salpingitis-induced infertility with qi stagnation and blood stasis syndrome based on the TLR4/MyD88/NF-&kappa;B/NLRP3 signa

Wenmin Yuan, Shangxin Dong, Nan Li, Li Liu, Haiyang Wang, Yan‐Hua Du
article en

Abstract

<sec> <title>目的</title> 观察膈下逐瘀汤加减方基于TLR4/MyD88/NF-κB/NLRP3信号通路对气滞血瘀型输卵管炎性不孕(SOI)大鼠输卵管组织结构的影响。 </sec> <sec> <title>方法</title> 制备慢性SOI病证结合模型,使用膈下逐瘀汤加减方和TLR4通路抑制剂TAK-242进行干预后,采集各组大鼠血浆、血清及输卵管组织,采用酶联免疫吸附测定法(ELISA)检测大鼠血清中白介素1β(IL-1β)、肿瘤坏死因子α(TNF-α)水平;血液流变学检测气滞血瘀状态;HE染色观察输卵管组织病理变化;免疫组化法检测TLR4、NLRP3表达水平;RT-pcr、WB检测TLR4、MyD88、NF-κB、NLRP3、Bax、Bcl-2 mRNA及蛋白表达水平;观察各组大鼠受孕率。 </sec> <sec> <title>结果</title> 与模型组大鼠相比,中药组血浆粘度、全血粘度3.0显著降低;中药组及抑制剂组血清IL-1β、TNF-α含量显著降低,组织中TLR4、MyD88、NF-κB、NLRP3、Bax mRNA及蛋白表达降低,Bcl-2 mRNA及蛋白表达升高,输卵管病理状态改善,大鼠受孕率增加。 </sec> <sec> <title>结论</title> 膈下逐瘀汤加减方能通过TLR4/MyD88/NF-κB/NLRP3通路治疗气滞血瘀型慢性SOI,减少凋亡,TAK-242可以发挥类中药作用改善疾病的炎性指标、病理状态,但是对中医证候无明显效果。 </sec>

Lishizhen medicine and materia medica researchVol. 36(7)
Openalex Percentile: Top 79%
Immune Response and Inflammation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.